Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602446 · ClinicalTrials.gov registry record · Phase 2
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00602446 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 4 participants.
The verdict
NCT00602446, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant. PURPOSE: This phase II trial is studying the side effects and how well deferasirox works in treating patients with iron overload after donor stem cell transplant.
Interventions
- DRUG deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00602446
The ClinicalTrials.gov registry entry for NCT00602446 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which deferasirox is the first listed.
NCT00602446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00602446 about?
NCT00602446 is a clinical study titled "Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant". RATIONALE: Deferasirox may be effective in treating iron overload caused by blood transfusions in patients who have undergone donor stem cell transplant. PURPOSE: This phase II trial is studying the side effects and how well deferasirox works in treating patients with iron overload after donor stem...
What is the current status of trial NCT00602446?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2007-08. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00602446?
The interventions under investigation include: deferasirox (DRUG).
Who is sponsoring clinical trial NCT00602446?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.